Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet Corporation (PODD) Q1 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and ...
Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compar...
Insulet misses first-quarter profit estimates as marketing costs weigh
Insulet Corp reported first-quarter profit that missed market expectations on Thursday, weighed by higher marketing expenses, sending shares of the medical device maker down 3.7% in extended trading.
Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Insulet (PODD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the...
Insulet (PODD) Rises Higher Than Market: Key Facts
In the most recent trading session, Insulet (PODD) closed at $173.42, indicating a +1.85% shift from the previous trading day.
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet (PODD) Outperforms Broader Market: What You Need to Know
Insulet (PODD) reachead $166.19 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High?
The consensus price target hints at a 38.9% upside potential for Insulet (PODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...
Here's Why You Should Buy Insulet (PODD) Stock Right Now
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall S...
Related Companies